glp-1 obesity drug news today oct 23 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 What is the pipeline for

68 Epidemiology of hypoglycaemic episodes leading to hospitalisations in Denmark over the last two decades M.H

until at least 2032, when the first main patent for the drug, held by Novo Nordisk,expires

In one study, people with obesity who received vitamin D supplements in addition to following a weight loss diet plan lost more weight and fat mass than the members of the placebo group, who only followed the diet plan

The STEP trials are testing semaglutide at the higher dose of 2.4 mg/week (as compared to 1.0 mg/week for the original diabetes indication), specifically for promoting weight loss, regardless of the presence of type 2 diabetes

In March 2024, we announced positive results from this Phase 1 MAD clinical trial of the oral tablet formulation of VK2735